Clinical Trials Logo

Neonatal Sepsis clinical trials

View clinical trials related to Neonatal Sepsis.

Filter by:

NCT ID: NCT05692128 Not yet recruiting - Neonatal Sepsis Clinical Trials

Frequency and Severity of Thrombocytopenia in Neonatal Sepsis

Start date: September 2023
Phase:
Study type: Observational

The aim of our study was to find the frequency of thrombocytopenia and its severity in neonates with sepsis

NCT ID: NCT05585957 Not yet recruiting - NEONATAL SEPSIS Clinical Trials

THE VALUE OF INTERLEUKIN 6 AS A DIAGNOSTIC MARKER IN NEONATAL SEPSIS

Start date: November 1, 2022
Phase: N/A
Study type: Interventional

Neonatal sepsis is a leading cause of neonatal mortality and continues to be a formidable problem for neonatologists and pediatricians world over. The prevalence of neonatal sepsis varies in different countries; in developed countries it is 1 to 10 cases per 1000 live births and in developing countries the incidence of neonatal septicemia increases to 49 to 170 cases per 1000 live births. The normal fetus is sterile until shortly before birth as the placenta and amniotic sac are highly effective barriers to infections. At birth, the newborn loses the protection afforded to it in the uterus and gets exposed to the microbial world.Neonatal sepsis is broadly divided into two types according to age of onset: Early-onset sepsis (<72 Hrs) and late-onset sepsis (≥72 hrs-28 days). Early-onset sepsis is acquired during fetal life, delivery, or at the nursery.Bacterial organisms causing NS may differ among countries, however, in most developing countries, gram-negative bacteria remain the major source of infection.To date, blood culture is the gold standard test for diagnosing sepsis, but it has some inherent limitations. It takes at least three or five days to be decisive and can be mistakenly negative because antibiotics are initiated empirically before collection and a well-developed microbiology laboratory is required.CRP is one of the most widely studied and applied acute phase proteins clinically, which can be induced by pre-inflammatory factor interleukin-6 (IL-6) to synthesize by liver cells, and it starts to rise in 12-24 hours of inflammatory response and reaches its peak at 48 hours.Interleukin-6 (IL-6) is a pleiotropic cytokine expressed by different cells in response to infections.

NCT ID: NCT05114057 Not yet recruiting - Acute Kidney Injury Clinical Trials

Use of NGAL for Fluid Dosing and CRRT Initiation in Pediatric and Neonatal AKI

Taking Focus 2
Start date: September 1, 2024
Phase: N/A
Study type: Interventional

This study will follow patients admitted to the PICU with sepsis, NICU with sepsis or after abdominal surgery, or CICU who are identified as being at risk for developing acute kidney injury. The investigators will use risk-stratification, biomarker testing, and a functional assessment to predict children and neonates who will become fluid overloaded and develop severe acute kidney injury.

NCT ID: NCT05089760 Not yet recruiting - Neonatal Sepsis Clinical Trials

Microbiology, Antimicrobial Resistance and Outcomes of Neonatal Sepsis in China

Start date: January 1, 2024
Phase:
Study type: Observational

Neonatal sepsis remains one of the most important cause of mortality and morbidities in China. This study will establish a prospective registral cohort of all infants with culture-proven neonatal sepsis in Chinese NICUs participating in the Chinese Neonatal Network (CHNN). The microbiology, antimicrobial resistance patterns and neonatal outcomes will be described in detail for this cohort.

NCT ID: NCT04105413 Not yet recruiting - Sepses, Neonatal Clinical Trials

Early Diagnosis of Neonatal Sepsis

Start date: September 30, 2019
Phase:
Study type: Observational

Sepsis is defined as a systemic inflammatory response syndrome (SIRS) associated with infection diagnosed either on microbiologic cultures or strong clinical evidence of an infection.

NCT ID: NCT04050488 Not yet recruiting - Clinical trials for Bronchopulmonary Dysplasia

Zinc Supplementation on Very Low Birth Weight Infant

Start date: August 20, 2019
Phase: Phase 4
Study type: Interventional

Premature birth is a major cause of neonatal death in addition to neonatal asphyxia and infections. Early in life, premature babies must get aggressive nutrition so that there is no extrauterine growth restriction (EUGR) in the Intrauterine Growth Restriction (IUGR) group compared to the non-IUGR group. Other factors that also play a role are long episodes of fasting, the fulfillment of nutrition (macro and micronutrients) from the start, time to start breastfeeding (ASI), duration of parenteral total administration, the incidence of respiratory distress syndrome and incidence of necrotizing enterocolitis. Zinc is one of the micronutrients which is very risky for deficiency in premature babies. Babies with zinc deficiency experience growth disorders as much as 67%. In India, infants who received zinc supplementation increased after being given 10 days of zinc supplementation and lower mortality rates in the group with supplementation. Very low birth weight babies and bronchopulmonary dysplasia who received zinc supplementation during the week showed good clinical progress and the growth rate also increased. The investigators believe this study has the potential for decreasing infant mortality from its current level and can be a growth indicator for preterm babies.

NCT ID: NCT04041765 Not yet recruiting - Inflammation Clinical Trials

IgM-Enriched Immunoglobulin for Neonatal Sepsis

Start date: September 2019
Phase: Phase 3
Study type: Interventional

This study compares giving prophylactic IgM enriched Intravenous Immunoglobulin (IVIG) with placebo in 1 hour after birth, in neonates with risk factors of Early-Onset Neonatal Sepsis (EONS). In addition to the intervention, standard regimen antibiotics are also given within 1 hour. The IVIG is given for 3 days and primary and secondary outcomes will be collected. Risk factors are both from maternal and neonate origin.

NCT ID: NCT03880305 Not yet recruiting - Neonatal Sepsis Clinical Trials

White Blood Cells and Platelets Indices as a Prognostic Factor in Neonatal Sepsis

Start date: April 1, 2019
Phase:
Study type: Observational [Patient Registry]

Sepsis is a complex condition initiated by a pathogen and mediated by cytokines followed by immune, inflammatory, and coagulation homeostasis disturbances, its evolution being dictated by a complicated balance between pro inflammatory and anti- inflammatory factors. Most of the short and long-term complications of the neonatal sepsis are strictly related to inflammatory mediators. Neonatal sepsis is associated with a mortality rate that ranges from 13 to 60% inspite of improved antibiotic therapy and an increased morbidity in survivors .

NCT ID: NCT03795285 Not yet recruiting - Neonatal SEPSIS Clinical Trials

The Role of Neutrophil CD64 and Soluble Triggering Receptor Expressed on Myeloid Cells 1 in Neonatal Sepsis

Start date: February 20, 2019
Phase:
Study type: Observational

Neonatal sepsis (NS) is a rather serious but relatively common health problem. Despite recent advances in the treatment of neonatal infection, mortality and comorbidities remain high.

NCT ID: NCT03498989 Not yet recruiting - Weight Gain Clinical Trials

Effect of Early Feeding of Breast Milk

Start date: June 21, 2018
Phase: N/A
Study type: Interventional

Breast milk is an extremely complex and highly variable biofliud that has evolved to nourish infants and protect them from disease whilst their own immune system matures. The composition of human breast milk changes in response to many factors, matching the infants requirement according to its age and other characteristics.